#
Title
1

Color and contrast-specific perimetry to probe retinal ganglion cell subtype vulnerability

2

Inequities in access to visual field testing and their outcome consequences

3

Low-Carb Diets and Nocturnal Blood Pressure Dips: Ocular Perfusion Risks and Benefits

4

Macronutrient Patterns and Intraocular Pressure: A Systematic Evaluation

5

Personalized Nutrition in Glaucoma: Nutrigenomic Interactions with Macronutrient Metabolism

6

Medium-Chain Triglycerides vs Long-Chain Fats: Rapid Ketosis and Visual Function

7

Protein Intake, Homocysteine, and Pseudoexfoliation Glaucoma Risk

8

mTOR/Autophagy Modulation by Amino Acids in RGC Degeneration

9

NR vs NMN vs Nicotinamide for Glaucoma: Which NAD+ Booster Has the Strongest Evidence?

10

How Useful Is OCT at Each Stage of Glaucoma?

11

New Glaucoma Treatments in 2026: What Patients Should Know About Longer-Lasting Eye Pressure Control

12

Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway

13

Substance P, Pain, and Neuroinflammation in Glaucoma

14

GLP-1 Peptides and Glaucoma Risk: What We Know and What to Watch

15

Nerve Growth Factor–Based Peptides and Optic Nerve Protection

16

Heat shock protein-derived peptides and autoimmunity in glaucoma

17

Endothelin pathway peptides and optic nerve head ischemia in glaucoma

18

MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

19

Senolytics and the Glaucoma Niche: Clearing Old Cells for Longer-Life Signals

20

Ketogenic Signals and Beta-Hydroxybutyrate: IOP, Neuroprotection, and Longevity Intersections

21

The Glaucoma Energy Crisis: How Pyruvate Rescues Failing Eyes (And Why Your Fitness Level Matters)

22

Photobiomodulation (670 nm) for Aging Retina: Lifespan Signals from Flies to Mammals

23

What’s New in Glaucoma Research in April 2026? What Patients Should Know

24

A New Clue in Glaucoma: Leaky Blood Vessels May Damage Vision

25

April 2026 Glaucoma Trial Launches: A Global Landscape Review

26

April 2026 Glaucoma Trial Launches: A Global Landscape Review

27

Therapeutic Mechanisms Debuting in April 2026 Glaucoma Trials

28

Gene- and Cell-Based Therapies Entering Glaucoma Trials in April 2026

29

Home Tonometers and Contact Lens Sensors in April 2026 Protocols

30

Washout and Rescue Protocols in April 2026 IOP-Lowering Studies

31

Hyperbaric Oxygen Therapy and Glaucoma: Mechanistic Rationale and Biological Plausibility

32

Oxidative Stress, Hormesis, and the Hyperoxia Paradox in Glaucoma

33

Soccer and Glaucoma: Endurance Gains Amid Collision Risks

34

Hiking and Glaucoma: Terrain, Altitude, and Sun Exposure

35

Running and Jogging with Glaucoma: Balancing Cardiovascular Gains and IOP Fluctuations

36

Road Cycling and Glaucoma: Aerobic Advantage with Posture and Safety Considerations

37

Snorkeling and Glaucoma: Gentle Aquatic Activity with Mask and Sunlight Considerations

38

SCUBA Diving and Glaucoma: Pressure, Perfusion, and Post-Surgical Precautions

39

Lap Swimming and Glaucoma: Cardiorespiratory Benefits vs. Goggle and Head Position Issues

40

Basketball and Glaucoma: Dynamic Cardio with Contact and Glare Considerations

41

General Resistance Training and Glaucoma: Building Strength While Managing IOP Spikes

42

High-Intensity Interval Training (HIIT) and Glaucoma: Short Bouts, Big Questions

43

Can Eye Blood Vessel Changes Warn of Future Glaucoma Damage Before Vision Tests Turn Abnormal?

44

Does Angle-Closure Risk Build Up Earlier in Life Than People Think?

45

Can Exercise, Better Sleep, and Stress Reduction Help in Glaucoma? What a New March 2026 Study Suggests

46

If One Person in the Family Has Glaucoma, Should Everyone Else Get Checked?

47

A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?

48

What Was Actually New in Glaucoma This Month? A Plain-English Guide to the Most Important March 2026 Updates

49

Why Is It So Hard to Prove a Treatment Protects the Optic Nerve in Glaucoma?

50

A New Way to Read Eye Scans in Glaucoma: Can 3D Nerve Fiber Shape Improve Detection?

51

Could Better Scan Databases Help Catch Glaucoma Earlier? What a New March 2026 Study Found

52

Does Eye Pressure Damage Show Up Before Vision Gets Worse? A New March 2026 Glaucoma Study Explains the Time Lag

53

A Cataract Lens That Also Treats Glaucoma? What the New BIM-IOL Study Means for Patients

54

Why Vision Restoration Is So Much Harder in Glaucoma Than in Some Other Eye Diseases

55

Eyes Wide Open: How Karpathy's Autoresearch Framework Could Democratize Glaucoma Research — A Blueprint for Patient-Led, AI-Driven Discovery in Vision Restoration

56

Can a Light-Sensing Drug Help Restore Vision? Understanding the Newest KIO-301 Research

57

A Treatment That Helped Some Blind Patients See More Light and Shape: What MCO-010 Means for Vision Restoration

58

Helping New Cells Survive: How Tiny Drug Carriers May Support Future Vision Repair in Glaucoma

59

Could Cell Transplants One Day Restore Vision in Glaucoma? A New Study Looks at One Major Roadblock

60

A New Glaucoma Implant Study: Can It Protect Vision, and Can It Bring Lost Vision Back?

61

What Is a 24-2 Visual Field Test

62

How Fast Does Glaucoma Progress

63

Perioperative Pitfalls: Supplements That Raise Bleeding Risk in Glaucoma Surgery

64

Does Diabetes Cause Glaucoma

65

Can You Have Glaucoma in One Eye

66

Zinc, Copper, and Optic Neuropathy: When Supplements Mimic Glaucoma Progression

67

How Long Does a Glaucoma Test Take

68

Which Is Worse Cataracts or Glaucoma

69

Does Glaucoma Cause Headaches

70

How to Test for Glaucoma

71

Is Glaucoma a Disability

72

Is Glaucoma Genetic

73

What Is Narrow Angle Glaucoma

74

What Are the Symptoms of Glaucoma

75

How to Prevent Glaucoma

76

What Does Glaucoma Look Like

77

What Causes Glaucoma

78

Magnesium and Glaucoma: A Systematic Review of Human Evidence

79

Antioxidant Vitamins and Minerals: Do A, C, E, Zinc, and Selenium Matter in Glaucoma?

80

Sodium, Blood Pressure, and Ocular Perfusion: Dietary Salt in Glaucoma Care

81

Soy Foods, Phytoestrogens, and Glaucoma in Women

82

Lifestyle Levers to Extend Visual Healthspan

83

Blue Zones and Centenarians: Ocular Phenotypes of Exceptional Agers

84

Metformin, Rapamycin, and Geroscience Drugs: Ocular Outcomes

85

ER-100 Clinical Trial for Glaucoma: What We Know So Far and What to Expect

86

Glaucoma Eye Drops, Dry Eye, and Sleep Quality: Exploring Hidden Connections and What Patients Can Do

87

The Ocular Microbiome, Inflammaging, and Surface Health

88

Methods of Visual Field Testing in Glaucoma: How They Differ and What Each Reveals

89

The Limitations of Visual Field Testing in Glaucoma: Frequency, Subjectivity, and What Gets Missed

90

Home Tonometry and Remote Monitoring in Glaucoma – A Patient-Centered Investigation

91

Predicting Glaucoma Before It Starts: How Close Are We to Genetic Risk Scores That Actually Change Patient Outcomes?

92

Glaucoma Clinical Trials Launched in 2025: A Complete Overview

93

Patterns of Vision Loss in Glaucoma: Large Blind Spots Versus Scattered Missing Points

94

How Fast Is AI Actually Progressing, and What Does It Mean for Glaucoma Patients and Researchers?

95

AI in Glaucoma: What's Working Now, What's Coming Next, and Where the Real Opportunities Lie

96

Glaucoma Vision Restoration: What's New in January 2026

97

Hydrogen Water Research Compiled: Studies, Dosages, Applications, and Outcomes

98

Pyruvate Supplementation for Glaucoma: Comparing Forms, Efficacy, and Global Availability

99

Nitric Oxide Pathway Supplements (L-Arginine, L-Citrulline) and Aqueous Outflow

100

Pyrroloquinoline Quinone (PQQ) and Mitochondrial Biogenesis in RGCs

101

Myopia and Glaucoma: When Nearsightedness Raises the Stakes

102

HDL cholesterol and apolipoprotein A-I: protective or paradoxical in glaucoma?

103

Complement proteins C3 and C4: systemic innate immunity and glaucoma progression

104

Systemic immune-inflammation index (SII) and the speed of RNFL loss

105

Coagulation markers (fibrinogen and D-dimer) and optic nerve microthrombosis

106

Redox Balance and Glaucoma: Is More Antioxidants Always Better for Your Eyes?

107

Red cell distribution width as a microvascular stress marker in glaucoma

108

Beyond the Marketing: Which Hydrogen Water Bottles Have Verified Test Results?

109

Hydrogen Water Buying Guide for Glaucoma-Focused Consumers: Science-First Approach

110

High-Sensitivity CRP: Systemic Inflammation and Glaucoma Neurodegeneration

111

ApoB, ApoA1, and Non-HDL Cholesterol: Refining Atherogenic Risk in Glaucoma Patients

112

Platelet Metrics (Mean Platelet Volume) and Microvascular Risk in Glaucoma

113

Uric Acid: Antioxidant Versus Pro-oxidant in Glaucoma

114

IGF-1, mTOR Signaling, and Neurodegeneration Across Eye and Brain

115

Oxidative Stress Biomarkers, HRV, and Retinal Ganglion Cell Loss

116

Stacking Blood-Thinning Supplements: Cumulative Bleeding Risk in Glaucoma Patients

117

Selective Laser Trabeculoplasty in the Era of OTC Blood Thinners: Hyphema and IOP Spikes

118

SLT as First-Line Therapy: Who Benefits and When to Repeat

119

Neuroprotection Beyond Pressure: What’s Real, What’s Hype

120

Dry Eye Can Fake Progression: Fix the Surface, Fix the Tests

121

Contact Lenses With Glaucoma: Timing Drops, Preservatives, and Comfort

122

Adherence That Sticks: Storage, Travel, and Tech Tools for Glaucoma Drops

123

Vasospasm, Cold Hands, and Normal-Tension Glaucoma: The Raynaud’s Connection

124

Exercise Smart: Aerobic vs Weightlifting, Valsalva, and Yoga Inversions

125

Sleep Posture Hacks: Head Elevation and Side-Sleeping Effects on Eye Pressure

126

The Nighttime Blood Pressure Dip: A Hidden Driver in Normal-Tension Glaucoma

127

Measuring What Matters: Beyond Visual Fields to Functional Vision

128

Hydration Habits: Water-Drinking Spikes and How to Sip Safely

129

Mastering Eye Drop Technique: Nasolacrimal Occlusion to Boost Efficacy and Safety

130

Vitamins C and E in Glaucoma: Antioxidants Revisited

131

Mirtogenol (Pycnogenol + Bilberry) and Eye Pressure: A Critical Appraisal

132

Caffeine, Coffee, and Tea: How Do They Impact Eye Pressure?

133

Palmitoylethanolamide (PEA) as an Adjunct in Glaucoma

134

Can Restoring Ocular Perfusion Restore Vision? OCT-A and Vascular Therapies

135

Cortical Plasticity and Perceptual Learning: Can the Brain Compensate for Optic Nerve Damage?

136

ROCK Inhibitors Beyond IOP: Axonal Regrowth, Perfusion, and Neuroprotection

137

Brain Stimulation for Glaucoma: tDCS, TMS, and Visual Cortex Modulation

138

Circadian Biology, ipRGCs, and Neuroprotection in Glaucoma

139

The 2024–2025 Pipeline for IOP-Independent Neuroprotection in Glaucoma

140

Forecasting Glaucoma Vision Restoration: 5-, 10-, and 20-Year Outlook

141

Nicotinamide and Mitochondrial Rescue: Can Metabolic Therapy Restore Function?

142

Artificial Vision for End-Stage Glaucoma: Retinal vs. Cortical Prostheses

143

Stem Cell–Derived RGC Transplantation: From Petri Dish to Optic Tract

144

Electrical Stimulation for Glaucoma: Signal Boost or True Neurorestoration?

145

Gene Therapy for Optic Nerve Regeneration: Modulating PTEN/mTOR, KLFs, and Sox11

146

Quercetin and Fisetin as Candidate Senolytics in Optic Nerve Aging

147

Citrus Bioflavonoids (Hesperidin, Diosmin) for Ocular Hemodynamics

148

Molecular Hydrogen and Redox Signaling in Ocular Neuroprotection

149

Anthocyanins and Bilberry Extracts: Retinal Resilience and Aging Microvasculature

150

Taurine and Retinal Ganglion Cell Survival Across the Lifespan

151

Green Tea Catechins (EGCG) for Neurovascular Health in Glaucoma and Aging

152

Melatonin, Circadian Rhythms, and Nocturnal IOP Dynamics

153

The Gut–Eye Axis: Probiotics, Metabolites, and Intraocular Pressure

154

Magnesium for Vascular Dysregulation in Glaucoma and Aging Circulation

155

Resveratrol and Sirtuin Pathways: From Trabecular Meshwork to Longevity

156

Macular Carotenoids (Lutein, Zeaxanthin, Meso-zeaxanthin) Beyond the Macula

157

Saffron (Crocins) in Optic Neuroprotection: Translating Retinal Evidence to Glaucoma

158

Safety, Interactions, and Regulatory Oversight of Glaucoma Supplements

159

Spermidine and Autophagy: A Longevity Nutrient for the Aging Eye

160

Curcumin and Curcuminoids: Anti-inflammatory Strategies for Glaucoma Neuroprotection

161

Vitamin D Status, Intraocular Pressure, and Neuroinflammation

162

N-Acetylcysteine and Glutathione: Fortifying Antioxidant Defenses in the Aging Eye

163

From Bench to Bedside: Translating Longevity Pathways to Glaucoma Supplements

164

Omega-3 Fatty Acids, Inflammation Resolution, and Glaucoma Progression

165

Citicoline (CDP-Choline) for Visual Pathway Support and Cognitive Aging

166

Alpha-Lipoic Acid: Redox Modulation and Neurovascular Support in Glaucoma

167

Creatine and Energy Buffering in Retinal and Optic Nerve Tissues

168

Astaxanthin for Oxidative Stress and Ocular Blood Flow

169

Designing Multi-Ingredient Neuroprotective Formulations for Glaucoma

170

B Vitamins, Homocysteine, and Vascular Dysregulation in Glaucoma

171

Ginkgo biloba for Ocular Perfusion and Visual Field Preservation: Promise and Precautions

172

Coenzyme Q10 as a Mitochondrial Adjunct in Glaucoma and Lifespan Health

173

Tele-Glaucoma and Home Monitoring in Aging Populations

174

Nicotinamide and NAD+ Boosting for Glaucoma Neuroprotection and Healthy Aging